Master Acute Tubular Necrosis with Picmonic for Medicine

Ischemic injury is a primary cause of acute tubular necrosis (ATN), occurring when renal blood flow is significantly reduced, resulting in cellular hypoxia and necrosis of tubular epithelial cells. This typically affects the proximal tubules and the thick ascending limb, which are the most metabolically active segments of the nephron. Common causes include severe hypotension, shock states such as sepsis, massive hemorrhage, and surgical procedures involving temporary clamping of the renal vasculature.

Nephrotoxic injury represents another major cause of ATN and occurs when tubular epithelial cells are directly damaged by toxins or medications. Substances such as aminoglycoside antibiotics, amphotericin B, cisplatin, radiographic contrast agents, and myoglobin from rhabdomyolysis are well-known culprits. The proximal tubules are most affected because they are responsible for active reabsorption and have high exposure to filtered toxins.

The diagnosis of ATN is supported by urine microscopy showing granular “muddy brown” casts, which consist of necrotic tubular epithelial cells and proteinaceous debris. These casts are considered pathognomonic for ATN and help distinguish it from pre-renal azotemia or post-renal causes of acute kidney injury.

ATN is classified as an intrinsic form of acute kidney injury, meaning the pathology lies within the renal parenchyma itself. Following the initial insult, patients progress through distinct phases of injury and recovery.

During the oliguric phase, urine output typically decreases to less than 400 mL per day (or <0.5 mL/kg/hour) due to acute tubular epithelial cell injury with necrosis and obstruction of tubules by cellular debris. This phase is characterized by rising BUN and creatinine, fluid overload (which may lead to hypertension), and electrolyte abnormalities such as hyperkalemia and metabolic acidosis, primarily due to impaired renal acid excretion.

The dominant mechanism is impaired acid (H⁺ and NH₄⁺) excretion. As renal tubular function deteriorates, hydrogen ion excretion decreases, resulting in metabolic acidosis. The inability to excrete potassium results in hyperkalemia, which can manifest as ECG changes and cardiac arrhythmias in severe cases.

In ATN, both BUN and creatinine rise as glomerular filtration rate declines. Importantly, the fractional excretion of sodium (FeNa) is typically greater than 2%, distinguishing ATN from pre-renal azotemia, where FeNa is less than 1%.

As with any acute kidney injury, the kidney cannot function to filter the blood properly, and so waste products build up in the bloodstream. This includes BUN and creatinine. The fractional excretion of sodium (FeNa) will also increase since the kidney cannot function normally to reclaim excreted sodium.

As regeneration of tubular epithelial cells begins, urine output increases markedly in the polyuric phase. Despite this rise in urine volume, the recovering tubules are unable to concentrate urine effectively, leading to large losses of water and electrolytes.

During this recovery phase, serum BUN and creatinine gradually decline toward normal levels. However, the high urine output can lead to hypokalemia and volume depletion if fluids and electrolytes are not carefully managed.

Patients in the polyuric phase are at risk for developing hypokalemia due to potassium loss in the urine.

Treatment for ATN revolves around supportive care for the clinical manifestations of renal failure. This includes control of hypertension, fluid overload, and electrolyte abnormalities. The underlying insult should be identified and corrected. In the case of nephrotoxic medications, they should be stopped. In severe cases of ATN, dialysis could be required.